Imago BioSciences is a clinical-stage biopharmaceutical company discovering and developing novel small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in the production of blood cells in the bone marrow. Imago is focused on improving the quality and length of life for patients with cancer and bone marrow diseases. Bomedemstat, an orally available, small molecule inhibitor of LSD1, is the lead product candidate discovered by Imago for the treatment of certain myeloproliferative neoplasms (MPNs), a family of related, chronic cancers of the bone marrow. Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia (NCT04254978) and myelofibrosis (NCT03136185). Bomedemstat has U.S. FDA Orphan Drug and Fast Track Designation for the treatment of ET and MF, European Medicines Agency (EMA) Orphan Designation for the treatment of ET and MF, and PRIority MEdicines (PRIME) Designation by the EMA for the treatment of MF. The company is based in South San Francisco, California.
Company profile
Ticker
IMGO
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
454915810
IMGO stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
23 Jan 23
EFFECT
Notice of effectiveness
17 Jan 23
25-NSE
Exchange delisting
11 Jan 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Jan 23
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Jan 23
POS AM
Prospectus update (post-effective amendment)
11 Jan 23
8-K
Completion of Acquisition or Disposition of Assets
11 Jan 23
SC 14D9/A
Tender offer solicitation (amended)
11 Jan 23
SC TO-T/A
Third party tender offer statement (amended)
11 Jan 23
SC 14D9/A
Tender offer solicitation (amended)
3 Jan 23
Latest ownership filings
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 23
SC 13G/A
Farallon Capital Partners, L.P.
1 Feb 23
SC 13G/A
BlackRock Inc.
26 Jan 23
SC 13G/A
BlackRock Inc.
20 Jan 23
SC 13D/A
Clarus Lifesciences III, L.P.
12 Jan 23
4
LAURIE KEATING
11 Jan 23
4
Enoch Kariuki
11 Jan 23
4
Amy E. Tapper
11 Jan 23
4
Hugh Rienhoff JR
11 Jan 23
4
Laura G. Eichorn
11 Jan 23
Financial summary
Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 7.29 mm | 7.29 mm | 7.29 mm | 7.29 mm | 7.29 mm | |
Cash burn (monthly) | 5.16 mm | 6.49 mm | 5.85 mm | 5.24 mm | 960.00 k | |
Cash used (since last report) | 96.25 mm | 121.13 mm | 109.12 mm | 97.77 mm | 17.91 mm | |
Cash remaining | -88.96 mm | -113.83 mm | -101.83 mm | -90.48 mm | -10.62 mm | |
Runway (months of cash) | -17.2 | -17.5 | -17.4 | -17.3 | -11.1 |
Institutional ownership, Q1 2023
17.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 106 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 49.86 mm |
Total shares | 5.99 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Omega Fund VI | 3.02 mm | $0.00 |
Frazier Healthcare VII | 2.97 mm | $49.86 mm |
Clarus Lifesciences III | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Jan 23 | Robert Jr. Baltera | Common Stock | Dispose U | No | No | 36 | 850 | 30.60 k | 0 | |
11 Jan 23 | Robert Jr. Baltera | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 15.65 | 11,904 | 186.30 k | 0 |
11 Jan 23 | Robert Jr. Baltera | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 16 | 23,809 | 380.94 k | 0 |
11 Jan 23 | Robert Jr. Baltera | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 1.68 | 114,075 | 191.65 k | 0 |
11 Jan 23 | Hsiangyi Chiang | Common Stock | Dispose U | No | No | 36 | 26,538 | 955.37 k | 0 | |
11 Jan 23 | Hsiangyi Chiang | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 22.76 | 23,500 | 534.86 k | 0 |
11 Jan 23 | Hsiangyi Chiang | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 15.45 | 91,500 | 1.41 mm | 0 |
11 Jan 23 | Hsiangyi Chiang | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 4.2 | 86,206 | 362.07 k | 0 |
11 Jan 23 | Jennifer Peppe | Common Stock | Dispose U | No | No | 36 | 150,188 | 5.41 mm | 0 | |
11 Jan 23 | Jennifer Peppe | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 2.1 | 23,562 | 49.48 k | 0 |